Skip to main content

Table 1 Study characteristics

From: Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review

Change in FEV1 Definition

Authors

Study Name

Geographic location

Follow-up (mths)

Patient N

Female (%)

Mean Age Years (SD)

Intervention (dose μg)

Change in FEV1 in ml (SD or 95%CI)

Mean change in FEV1 (ml)

Auffarth et al 1991 [21]

–

Netherlands

3

24

0.04

57.0 (8.2)

Placebo

-120 (230)

 

Bud (1600)

15 (110)

Cazzola et al 2000 [22]

–

Italy

3

80

11.6

64.2 (6.3)

Sal (50)

163 (80 to 245)

Sal/FP (50/250)

188 (89 to 287)

Sal/FP (50/500)

239 (183 to 296)

Lee et al 2016 [23]

–

China, Hong Kong, Indonesia, South Korea, Thailand

3

577

4.3

66.8 (8.3)

Tio (18)

80 (27)

Tio + bud/form (18 + 160/4.5)

160 (29)

Bourbeau et al 1998 [24]

–

Canada

6

79

21.5

66.0 (8.0)

Placebo

0–3 months: −1(−65 to 62)

0–6 months:12(− 61 to 85)

Bud (400)

0–3 months: −13(−59 to 33)

0–6 months:8(−51 to 68)

Ohar et al 2014 [25]

–

United States, Argentina, Norway

6.5

639

46

62.9 (9.2)

Sal (50)

40 (342)

FP/Sal (250/50)

140 (372)

Vestbo et al 2005 [26]

TRISTAN

Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Lithuania, Netherlands, New Zealand, Norway, Poland, Russia, South Africa, Spain, Sweden, Switzerland, IK

12

1465

27.6

63.2 (8.6)

Placebo

−65 (−200 to 85)

Sal (50)

0 (− 130 to 140)

FP (500)

0 (−160 to 160)

Sal/FP (50/500)

80 (−50 to 250)

Rate of FEV1 change (ml/year)

Vestbo et al 2017 [27]

TRINITY

Argentina, Belarus, Bulgaria, Croatia, Germany, Hungary, Italy, Mexico, Poland, Romania, Russia, Slovakia, Turkey, UK, Ukraine

12

2691

23.6

63.2 (8.6)

Tio (18)

21 (3 to 39)

Fixed: Beclo/FP/gly bro (100/6/12.5)

82 (65 to 100)

Open: Becl/FP/Tio (100/6/18)

85 (31 to 110)

Wise et al 2000 [28]

Lung Health Study

North America, Canada

12

1116

36.9

56.3 (6.8)

Placebo

−47 (70.8)

Triamcinolone acetonide (600)

−44.2 (69.8)

Weir et al 1999 [29]

–

UK

24

98

25.5

66.6 (7.0)

Placebo

−56.9 (15)

    

Becl (750)

−20.6 (16)

Renkema et al 1996 [30]

–

Netherlands

24

59

0

56.0 (8.6)

Placebo

−60 (− 570 to 140)

Bud (800)

−30 (−180 to 870)

Bud + oral prednisolone (800/5)

−40 (−340 to 60)

Burge PS et al 2000 [31]

ISOLDE

UK

36

751

25.4

63.7 (7.1)

Placebo

−59 (30.8)

FP (500)

−50 (28.7)

Calverley PM et al 2003 [32]

ISOLDE

UK

36

751

25.3

63.7 (7.1)

Placebo

−46

FP (500)

−51

Pauwels et al 1999 [33]

–

Belgium, Denmark, Finland, Italy, Netherlands, Norway, Spain, Sweden, UK

36

1277

27.2

52.5 (7.6)

Placebo

0–6 months: −81

9–36 months: −69

 

Bud (400)

0–6 months: 17

9–36 months: −57

Vestbo 1999 [34]

CCHS

Denmark

36

290

39.7

59.1 (9)

Placebo

−49.1

 

Bud (400)

−46.0

Calverley et al 2018 [35] & Vestbo et al 2016 [6]

SUMMIT

US, Argentina, Australia, Austria, Belarus, Belgium, Bosnia & Herzegovina, Bulgaria, Canada, Chile, China, Columbia, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Latvia, Malaysia, Macedonia, Mexico, Netherlands, Philippines, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey Ukraine, UK, Vietnam

48

16,485

25.5

65.0 (8.0)

Placebo

−46 (160.3)

Vil (25)

−47 (154.0)

FF (100)

−38 (154.3)

FF/Vil (100/25)

−38 (154.1)

Shaker et al 2009 [36]

–

Denmark

48

254

42

63.6 (7.4)

Placebo

−56 (−72 to −40)

  

Bud (400)

−54 (−69 to-40)

  1. Notes: 2 included studies (Calverley 2018, Vestbo 2016) were analyses on the same population and reported the same change in FEV1 estimates
  2. Abbreviations: FP Fluticasone proprionate, FF Fluticasone furoate, Sal Salmeterol, Bud Budesonide, Becl Beclomethasone, TIO Tiotropium, Vil Vilanterol, Mom mometasone, Form formaterol., UMEC umeclidinium, Gly Br glycopyyronium bromide, Ol olodaterol